JO3145B1 - مركبات مفيدة لتثبيط chk1 - Google Patents

مركبات مفيدة لتثبيط chk1

Info

Publication number
JO3145B1
JO3145B1 JOP/2011/0323A JOP20110323A JO3145B1 JO 3145 B1 JO3145 B1 JO 3145B1 JO P20110323 A JOP20110323 A JO P20110323A JO 3145 B1 JO3145 B1 JO 3145B1
Authority
JO
Jordan
Prior art keywords
compounds useful
inhibiting chk1
chk1
inhibiting
useful
Prior art date
Application number
JOP/2011/0323A
Other languages
English (en)
Inventor
Joseph Sajan
Samajdar Susanta
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3145B1 publication Critical patent/JO3145B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid

Abstract

يقدم الاختراع الحالي مركب أمينو بيرازول، أو ملح مقبول صيدليًا منه، والذي يُثبِّط Chk1 ويكون مفيدًأ في علاج السرطان.
JOP/2011/0323A 2010-11-08 2011-10-27 مركبات مفيدة لتثبيط chk1 JO3145B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41113710P 2010-11-08 2010-11-08

Publications (1)

Publication Number Publication Date
JO3145B1 true JO3145B1 (ar) 2017-09-20

Family

ID=45044707

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0323A JO3145B1 (ar) 2010-11-08 2011-10-27 مركبات مفيدة لتثبيط chk1

Country Status (22)

Country Link
US (1) US9067920B2 (ar)
EP (1) EP2638033B1 (ar)
JP (1) JP5792316B2 (ar)
KR (1) KR101533166B1 (ar)
CN (1) CN103180311B (ar)
AR (1) AR083575A1 (ar)
AU (1) AU2011326230B2 (ar)
BR (1) BR112013010009B1 (ar)
CA (1) CA2816944C (ar)
DK (1) DK2638033T3 (ar)
EA (1) EA022096B1 (ar)
ES (1) ES2541414T3 (ar)
HR (1) HRP20150530T1 (ar)
JO (1) JO3145B1 (ar)
ME (1) ME02119B (ar)
MX (1) MX2013005181A (ar)
PL (1) PL2638033T3 (ar)
PT (1) PT2638033E (ar)
RS (1) RS54012B1 (ar)
SI (1) SI2638033T1 (ar)
TW (1) TWI501956B (ar)
WO (1) WO2012064548A1 (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EP3411036B1 (en) 2016-02-04 2021-12-29 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
CA3200498A1 (en) 2020-11-30 2022-06-02 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
WO2023120696A1 (ja) * 2021-12-24 2023-06-29 住友ファーマ株式会社 二環性骨格を有する１ｈ－ピラゾール－３－アミン誘導体
WO2023229032A1 (ja) * 2022-05-27 2023-11-30 住友ファーマ株式会社 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000933A (es) * 2003-07-25 2006-03-30 Pfizer Compuestos de aminopirazol y uso como inhibidores de chk1.
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Ｃｈｋ１阻害剤であるチオフェン誘導体
DE602005011279D1 (de) * 2004-06-04 2009-01-08 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
JP2008540391A (ja) * 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1

Also Published As

Publication number Publication date
HRP20150530T1 (hr) 2015-06-19
CA2816944A1 (en) 2012-05-18
PL2638033T3 (pl) 2015-09-30
SI2638033T1 (sl) 2015-05-29
KR101533166B1 (ko) 2015-07-01
AR083575A1 (es) 2013-03-06
BR112013010009B1 (pt) 2021-10-19
ME02119B (me) 2015-10-20
CN103180311A (zh) 2013-06-26
AU2011326230B2 (en) 2015-02-19
AU2011326230A1 (en) 2013-05-09
PT2638033E (pt) 2015-06-01
US20130190262A1 (en) 2013-07-25
CN103180311B (zh) 2014-08-20
TWI501956B (zh) 2015-10-01
EP2638033A1 (en) 2013-09-18
DK2638033T3 (en) 2015-04-27
EA201390499A1 (ru) 2013-08-30
JP5792316B2 (ja) 2015-10-07
JP2013541586A (ja) 2013-11-14
EA022096B1 (ru) 2015-10-30
TW201305138A (zh) 2013-02-01
MX2013005181A (es) 2013-10-17
EP2638033B1 (en) 2015-04-08
RS54012B1 (en) 2015-10-30
US9067920B2 (en) 2015-06-30
KR20130099146A (ko) 2013-09-05
WO2012064548A1 (en) 2012-05-18
BR112013010009A2 (pt) 2020-09-29
ES2541414T3 (es) 2015-07-20
CA2816944C (en) 2015-12-22

Similar Documents

Publication Publication Date Title
TN2011000298A1 (en) Compounds useful for inhibiting chk1
MX351892B (es) Combinaciones de compuestos inhibidores de akt y abiraterona y metodos de uso.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
PH12015502091A1 (en) Cdc7 inhibitors
TN2012000622A1 (en) Combinations of kinase inhibitors for the treatment of cancer
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
MX355728B (es) Inhibidores de cinasas.
MY181898A (en) Heterocyclic compounds and uses thereof
MX2019010602A (es) Inhibidores de cdk.
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
IN2014DN10670A (ar)
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX2015007053A (es) Compuestos dimericos.
EA201492104A1 (ru) Ингибитор jak1/2
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
PH12015500399A1 (en) Azaindolines
MX2013015357A (es) Terapia de combinacion.
MX2015007054A (es) Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
TN2013000515A1 (en) Notch pathway signaling inhibitor compound
CY1116362T1 (el) Ενωσεις χρησιμες στην αναστολη της chk1
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
TN2011000545A1 (en) Vinyl indazolyl compounds